IP Library Granted Patent US 9,573,942
Granted Patent B2
US 9,573,942 · App. 14/566,400 · Granted Feb 21, 2017

HIV inhibiting 5-amido substituted pyrimidines

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,573,942
App. No.
14/566,400
Granted
Feb 21, 2017
Kind
B2
Abstract

This invention concerns pyrimidine derivatives of formula having HIV (Human Immunodeficiency Virus) replication inhibiting properties, the preparation thereof and pharmaceutical compositions comprising these compounds.

Claims (18)

1. A compound having the following structure:

wherein:

R 5 is selected from C 3-7 cycloalkyl; C 1-6 alkyloxy; aryl; Het; C 1-6 alkyl substituted with a radical selected from hydroxy, C 1-6 alkyloxy, cyano, amino, mono- and di-C 1-6 alkylamino, C 1-6 alkylcarbonylamino, aryl, Het, dioxolanyl optionally substituted with one or two C 1-6 alkyl radicals, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, piperazinyl optionally substituted with C 1-6 alkyl or C 1-6 alkylcarbonyl, C 1-6 alkyloxycarbonyl, arylC 1-6 alkyloxycarbonyl, or C 3-7 cycloalkyl; and is C 1-6 alkyl substituted with two C 1-6 alkyloxy radicals;

R 6 is selected from hydrogen and C 1-6 alkyl; or

R 5 and R 6 taken together with the nitrogen atom to which they are attached form pyrrolidinyl; piperidinyl; morpholinyl; piperazinyl; or piperazinyl optionally substituted with C 1-6 alkyl or C 1-6 alkylcarbonyl.

2. A compound according to claim 1 , wherein:

R 5 is C 3-7 cycloalkyl; C 1-6 alkyloxy; aryl; Het; C 1-6 alkyl substituted with a radical selected from hydroxy, C 1-6 alkyloxy, cyano, di-C 1-6 alkylamino, C 1-6 alkylcarbonyl amino, aryl, Het, dioxolanyl substituted with two C 1-6 alkyl radicals, tetrahydrofuranyl, pyrrolidinyl, C 1-6 alkyloxycarbonyl, and C 3-7 cycloalkyl;

R 6 is hydrogen or C 1-6 alkyl; or

R 5 and R 6 taken together with the nitrogen atom to which they are substituted form morpholinyl; piperazinyl substituted with C 1-6 alkyl.

3. A compound according to claim 1 , wherein R 5 is C 3-7 cycloalkyl; C 1-6 alkyloxy; C 1-6 alkyl substituted with a radical selected from hydroxy, C 1-6 alkyloxy, cyano, C 1-6 alkylcarbonylamino, aryl, Het, C 1-6 alkyloxycarbonyl; and R 6 is hydrogen.

4. A compound according to claim 1 , wherein each Het independently is pyridyl, thienyl, thiazolyl, furanyl, each of which may be optionally substituted with a radical selected from C 1-6 alkyl.

5. A compound according to claim 1 , wherein each aryl independently may be phenyl optionally substituted with C 1-6 alkylamino, mono- or di-C 1-6 alkyl-amino, C 1-6 alkyloxy, aminosulfonyl, Het, the latter more in particular being thiadiazolyl.

6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient a therapeutically effective amount of a compound as claimed in claim 1 .

7. A compound according to claim 1 , having the following structure:

8. A compound according to claim 1 , having the following structure:

9. A compound according to claim 1 , having the following structure:

10. A compound according to claim 1 , having the following structure:

11. A compound according to claim 1 , having the following structure:

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2015
From: JANSSEN R & D IRELAND
To: JANSSEN SCIENCES IRELAND UC
Reel/Frame 035496/0382 →